The website www.sympany.ch cannot be displayed correctly. Please update your browser: https://browsehappy.com
The Meconex Board of Directors has appointed Heidi Zbinden as the new CEO from the end of April 2020. The experienced executive and proven industry expert is taking over from Daniel Uebersax, who has been acting Meconex CEO since October 2019. Meconex covers a wide range of medical services.
Basel, 24 April 2020 – Heidi Zbinden is taking over as CEO of Meconex AG, a subsidiary of the Sympany Group, from 27 April 2020. The business graduate with an International Executive MBA has many years of leadership and management experience and is ideally qualified to take on the challenges of the health market and sector, not least because she is a member of the Board of the Swiss Health Quality Association SHQA. Before moving to Meconex, she was Managing Director of a global pharmaceutical company in the DACH region (Germany, Austria, Switzerland) and a member of the European Management Team.
Christian Meindl, Chairman of the Meconex Board, is really looking forward to working with her: “We are convinced that Heidi Zbinden will bring about the ideal conditions to move Meconex forward in a decisive way in the next few years.”
Daniel Uebersax, who has held the role of acting CEO since October 2019, will now focus again on his tasks as a member of the management team and Operational Manager of Prevomed, the occupational health and preventative medicine division of Meconex. “He took over the additional duties of acting CEO with great gusto and successfully spearheaded Meconex in this challenging time,” said Christian Meindl. “I would like to thank Daniel Uebersax on behalf of the Board of Directors.”